BioCentury | Apr 11, 2005
Product Development

Not bound to onercept

Although Serono S.A. had believed the binding and structure of its onercept TNF-binding protein looked more appealing than existing anti- TNF alpha treatments, the company halted development of the compound in psoriasis after it proved...
BioCentury | Mar 21, 2005
Regulation

Clinically challenged

When the EU introduced its draft clinical trial directive in 2001, academic institutions argued that the new procedures and requirements would add excessive paperwork and costs. The directive was put in place last May, and...
Items per page:
1 - 2 of 2
BioCentury | Apr 11, 2005
Product Development

Not bound to onercept

Although Serono S.A. had believed the binding and structure of its onercept TNF-binding protein looked more appealing than existing anti- TNF alpha treatments, the company halted development of the compound in psoriasis after it proved...
BioCentury | Mar 21, 2005
Regulation

Clinically challenged

When the EU introduced its draft clinical trial directive in 2001, academic institutions argued that the new procedures and requirements would add excessive paperwork and costs. The directive was put in place last May, and...
Items per page:
1 - 2 of 2